Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina

Background: Gam-COVID-Vac (SPUTNIK V) has been granted emergency use authorization in 70 nations and has been administered to millions worldwide. However, there are very few peer-reviewed studies describing its effects. Independent reports regarding safety and effectiveness could accelerate the fina...

Descripción completa

Detalles Bibliográficos
Autores: Chahla, Rossana Elena, Tomas Grau, Rodrigo Hernán, Cazorla, Silvia Ines, Ploper, Diego, Vera Pingitore, Esteban, Aguilar López, Mónica, Aznar, Patricia, Alcorta, María Elena, Velez, Eva Maria del Mar, Stagnetto, Agustín, Avila, Cesar Luis, Maldonado Galdeano, María Carolina, Socias, Sergio Benjamin, Heinze, Dar, Navarro, Silvia Adriana, Llapur, Conrado Juan, Costas, Dardo, Flores, Isolina, Edelstein, Alexis, Kowdle, Shreyas, Perandones, Claudia, Lee, Benhur, Apfelbaum, Gabriela, Mostoslavsky, Raul, Mostoslavsky, Gustavo, Perdigon, Gabriela del Valle, Chehin, Rosana Nieves
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/172919
Acceso en línea:http://hdl.handle.net/11336/172919
Access Level:acceso abierto
Palabra clave:COVID-19
GAM-COVID-VAC
HUMORAL INMUNE RESPONSE
LONG TERM IMMUNITY
RBD SPIKE
SARS-COV-2
SEROCONVERSION
SPUTNIK V
https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
Descripción
Sumario:Background: Gam-COVID-Vac (SPUTNIK V) has been granted emergency use authorization in 70 nations and has been administered to millions worldwide. However, there are very few peer-reviewed studies describing its effects. Independent reports regarding safety and effectiveness could accelerate the final approval by the WHO. We aimed to study the long-term humoral immune response in nay¨ve and previously infected volunteers who received SPUTNIK V. Methods: Humoral immune responses, assayed by anti-SARS-CoV-2-spike-RBD IgG ELISA and neutralization assays, were measured in 602 healthcare workers at 0, 14, 28, 60 and 180 days after receiving SPUTNIK V between December 2020 and July 2021 in Tucuman, Argentina. Findings: Seroconversion was detected in 97% of individuals after 28 days post-vaccination (dpv) (N = 405). Anti-RBD titers began to decrease after 60 dpv (N = 328), but remained detectable in 94% at 90 dpv (N = 224). At 180 dpv, anti-RDB titers persisted in 31% (N = 146). Previous infection triggered an increased immune response to the first dose and increased neutralization activity against variants of concern (VOC). Second doses in previously infected individuals further increased titers, even 90 dpv (N = 75). Basal antibody titers had more influence on postvaccination anti-RBD responses than the time elapsed between diagnosis and vaccination (N = 274). Interpretation: Data presented herein provides essential knowledge regarding the kinetics of antibodies induced by SPUTNIK V up to six months after immunization, and suggests that when considering one-dose vaccination policies for individuals with previous SARS-CoV-2 infection, serological studies to determine basal titers may be important, independent of when diagnosis occurred.

Similares en LA Referencia